What are the common acute and chronic side effects of oxaliplatin and how should they be monitored and managed?

Oxaliplatin Side Effects

Overview

Oxaliplatin causes two distinct types of neurotoxicity—an acute cold-triggered sensory neuropathy and a cumulative dose-dependent chronic peripheral neuropathy—along with hematologic toxicity, gastrointestinal effects, and rare but serious complications including pulmonary toxicity, posterior reversible encephalopathy syndrome, and cardiac events. 1

---

Acute Neurotoxicity (Cold-Triggered)

Clinical Presentation

• Acute peripheral sensory neuropathy occurs in the majority of patients and is uniquely triggered or exacerbated by cold exposure 1, 2
• Manifests as paresthesias and dysesthesias in the extremities and perioral region (around the mouth) 2, 3
• Symptoms include tingling, burning sensations, and odd feelings in the tongue 1
• Can cause jaw tightness, difficulty swallowing, breathing problems, or saying words 1
• This acute form is rapidly reversible between treatment cycles without persistent impairment 2, 3

Cold Avoidance Strategies

The FDA label provides specific instructions to minimize acute symptoms 1:

• Cover yourself with a blanket during oxaliplatin infusion 1
• Do not breathe deeply when exposed to cold air 1
• Wear warm clothing, gloves, and cover mouth/nose with a scarf in cold weather 1
• Avoid ice chips; drink fluids warm or at room temperature through a straw 1
• Wear gloves when handling items from freezer or refrigerator 1
• Be aware that metal objects (car doors, mailboxes) are cold to touch 1
• Do not run air conditioning at high levels 1

---

Chronic Cumulative Neurotoxicity (Dose-Limiting)

Characteristics

• Chronic peripheral sensory neuropathy is the dose-limiting toxicity of oxaliplatin, occurring predictably with cumulative doses 4, 2
• Grade 3 neurotoxicity occurs in 10-20% of patients at cumulative doses of 750-850 mg/m² 4
• Affects all patients receiving doses ≥540 mg/m² over four or more cycles 5
• Symptoms include persistent numbness, pain, tingling, and burning in hands and feet 1
• Can cause problems with walking, fall-related injuries, and impaired activities of daily living 1

Reversibility

• Unlike cisplatin, oxaliplatin-induced chronic neuropathy is more rapidly and completely reversible 2
• 82% of patients experience regression within 4-6 months after discontinuation 5
• 41% achieve complete recovery within 6-8 months 5
• Median time to recovery is 13 weeks after treatment discontinuation 6

Management Strategy: Stop-and-Go Approach

Discontinuation of oxaliplatin after 3 months of therapy is strongly recommended to prevent intolerable neurotoxicity, while maintaining fluoropyrimidine therapy 4:

• The "stop-and-go" approach decreases neurotoxicity without affecting overall survival 4
• Oxaliplatin should be stopped before intolerable toxicity occurs, with individual duration dependent solely on the degree of cumulative neurotoxicity and recovery 4
• Patients experiencing neurotoxicity should not receive subsequent oxaliplatin until near-total resolution occurs 4
• At disease progression during fluoropyrimidine maintenance, oxaliplatin may not be reapplicable if significant neurotoxicity persists 4

Failed Prophylactic Interventions

A Cochrane Review found that none of the proposed chemoprotective agents prevent or limit oxaliplatin neurotoxicity 4:

• Calcium/magnesium infusions do not reduce cumulative sensory neurotoxicity and are not recommended 4
• Other ineffective agents include acetylcysteine, amifostine, glutathione, Org 2766, oxycarbazepine, diethyldithiocarbamate, and vitamin E 4

---

Hematologic Toxicity

Myelosuppression

• Severe low blood cell counts are common when oxaliplatin is combined with fluorouracil and leucovorin, potentially leading to serious infection and death 1
• Grade 3/4 neutropenia occurs in 41.7-48% of patients receiving FOLFOX regimens 7, 6
• Thrombocytopenia is rare but may occur after multiple cycles 6
• Blood counts must be monitored before starting treatment and before each cycle 1

Febrile Neutropenia Management

• Contact physician immediately for fever >100.9°F (38.3°C) or prolonged fever >100.4°F (38°C) for more than one hour 1
• Warning signs of infection include chills, sore throat, cough with mucus, burning on urination, redness/swelling at IV site, or persistent diarrhea 1
• The risk of febrile neutropenia with oxaliplatin-based regimens is <20% unless additional risk factors are present, so routine G-CSF prophylaxis is not indicated 4

---

Gastrointestinal Toxicity

Common Effects

• Nausea and vomiting are usually mild to moderate and readily controlled with standard antiemetics 6
• Diarrhea occurs in 10-28% of patients with CapeOX regimens 8
• Grade 3/4 diarrhea occurs in approximately 12% of patients 7
• Mouth sores (mucositis/stomatitis) occur in up to 6% of patients 7
• 5-Fluorouracil contributes significantly more to gastrointestinal toxicity than single-agent oxaliplatin 6

Chemotherapy-Induced Diarrhea Management

• Loperamide, octreotide, and tinctura opii are recommended treatments 4
• Frequency of severe diarrhea (grade 3-5) is 30% or higher, especially with 5-FU bolus or irinotecan combinations 4

---

Hand-Foot Syndrome (with Capecitabine)

• Hand-foot syndrome occurs in 31% of patients receiving CapeOX 8
• Prophylactic basic skin care should be applied 4
• Pyridoxin or urea/lactic acid-based topical keratolytic agents have not shown activity in preventing hand-foot syndrome 4
• Celecoxib showed superiority to placebo in a phase II study but cannot be recommended as standard prophylaxis yet 4

---

Rare but Serious Complications

Posterior Reversible Encephalopathy Syndrome (PRES)

PRES is a rare neurological emergency requiring immediate medical attention 1:

• Symptoms include headache, confusion, seizures, and vision problems (blurriness or vision loss) 1
• Contact physician immediately if these symptoms develop 1

Pulmonary Toxicity

• Oxaliplatin can cause lung problems that may lead to death 1
• Warning signs include shortness of breath, wheezing, and cough 1
• Immediate physician notification is required for respiratory symptoms 1

Cardiac Toxicity

• Oxaliplatin can cause heart problems that have led to death 1
• Seek immediate medical help for fainting, irregular heartbeat, or chest pain 1
• Cardiac monitoring may be necessary for patients with pre-existing heart conditions 1

Hepatotoxicity

• Liver function tests should be checked at treatment initiation and before each course as needed 1
• Changes in liver function tests are common side effects 1

Rhabdomyolysis

• Oxaliplatin can cause muscle damage leading to death 1
• Warning signs include muscle pain and swelling with weakness, fever, red-brown urine, decreased urine output, or trouble urinating 1
• Immediate physician notification is required 1

Hemorrhage

• Bleeding problems can occur when oxaliplatin is combined with fluorouracil and leucovorin, potentially leading to death 1
• Risk increases if taking blood thinners 1
• Warning signs include blood in stools, pink/brown urine, unexpected or severe bleeding, vomiting blood, coughing up blood, increased bruising, dizziness, weakness, confusion, speech changes, or persistent headache 1

Nephrotoxicity

• Unlike cisplatin, oxaliplatin does not cause significant nephrotoxicity and can be administered without hydration 3, 6
• No significant renal toxicity has been observed in clinical trials 3

Ototoxicity

• No significant ototoxicity has been observed with oxaliplatin, unlike cisplatin 3

---

Monitoring Requirements

Before Each Cycle

• Complete blood counts to assess for myelosuppression 9, 1
• Liver function tests 9, 1
• Renal function and electrolytes 9
• Assessment for peripheral neuropathy severity 9
• Performance status evaluation 9

Tumor Response Evaluation

• CT scan with contrast after 2-3 months of treatment 9
• CEA levels if initially elevated 9

---

Fertility Considerations

• Oxaliplatin may cause fertility problems in males and females 1
• Discuss fertility preservation options before starting treatment 1

---

Key Clinical Pearls

The predictability and reversibility of oxaliplatin neurotoxicity allows for strategic treatment planning using the stop-and-go approach 2:

• Discontinue oxaliplatin after 3-4 months while continuing fluoropyrimidine to minimize cumulative neurotoxicity 4, 8
• This strategy maintains disease control while reducing long-term neurological complications 4
• Neurotoxicity, not tumor progression, may become the dominant treatment-limiting issue in first-line therapy, especially with the addition of bevacizumab prolonging progression-free survival 2